This presentation is delivered by GossamerBio, an industry partner of PHA Europe. They are in the process of developing a new PH medication that is based on a well-established component and is administered as an inhaled drug. During the presentation, Gossamer provides details about their drug and discusses their TORREY phase 2 study. The presentation concludes with an engaging Q&A session lasting almost 56 (!) minutes.
Patient association
Improved quality of PH care
Presenter: | Matt Granato |
---|---|
Presentation date: | November 2024 |
Length: | 66 minutes |
Q&A: | Yes |
Difficulty level (1-5): | 2 |
Subtitled: | No |
Dubbing: | No |
Tag(s): | Patient association |